Evidence map›Paper›PMID 29417827›Full record

ArticleFuture oncology (London, England)2018

Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.

Scott C Flanders, Janet Kim, Samuel Wilson, Jeffrey Braziunas, Sheldon Greenfield, John Billimek, Stanislav Lechpammer, Daniel W Lin, Lawrence Karsh, David I Quinn and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Scott C FlandersAstellas Pharma, Inc., Northbrook, IL 60062, USA.
Janet KimAstellas Pharma, Inc., Northbrook, IL 60062, USA.
Samuel WilsonAstellas Pharma, Inc., Northbrook, IL 60062, USA.
Jeffrey BraziunasAstellas Pharma, Inc., Northbrook, IL 60062, USA.
Sheldon GreenfieldHealth Policy Research Institute, University of California, Irvine, CA 90024, USA.
John BillimekHealth Policy Research Institute, University of California, Irvine, CA 90024, USA.
Stanislav LechpammerMedivation, Inc., which was acquired by Pfizer, Inc. in September 2016, San Francisco, CA 94105, USA.
Daniel W LinDepartment of Urology, University of Washington, Seattle, WA 98195, USA.
Lawrence KarshThe Urology Center of Colorado, Denver, CO 80211, USA.
David I QuinnNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA.
Daniel ShevrinMedical Oncology, North Shore University Health System, Evanston, IL 60201, USA.
Neal D ShoreCarolina Urologic Research Center, Myrtle Beach, SC 29572, USA.
James T SymanowskiLevine Cancer Institute, Carolinas HealthCare System, Charlotte, NC 28025, USA.
David F PensonDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37250, USA.

Funding

TRAINING-PULMONARY CELL &MOLECULAR BIOLOGY &PHYSIOLOGYT32HL007741 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI DUDLEY, R. ADAMS, INGBAR, DAVID H · 1994 to 2023
$13.9M
NHLBI NIH HHS T32 HL007741
6 · The paper itself

Abstract

aimTo validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients. PATIENTS &

methodsBaseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET).

resultsBaseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0.001) and FACT-P subscale/total (p < 0.020) scores. There was a significant decreasing linear trend in SF12v2 and FACT-P scores over the categories based on TIBI-CaP quartiles of comorbidity burden (from 'least' to 'severe').

conclusionThe TIBI-CaP is a valid measure of comorbidity burden in patients with CRPC in the real world.

Indexed as

Cost of IllnessAgedAged, 80 and overComorbidityHumansMaleMiddle AgedProstatic Neoplasms, Castration-ResistantPublic Health SurveillanceQuality of LifeRegistriesRisk FactorsSocioeconomic FactorsUnited Statescastration-resistant prostate cancerCRPCTIBI-CaPtotal illness burden index for prostate cancerTRUMPET registry

Identifiers

PMID29417827
PMCPMC5941708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.